Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aesther Healthcare Acquisition Corp. stock logo
AEHA
Aesther Healthcare Acquisition
$9.96
$10.25
$8.20
$14.22
$131.78M0.04434,237 shs1.29 million shs
Affimed stock logo
AFMD
Affimed
$0.18
-34.9%
$0.25
$0.07
$5.48
$2.92M2.074.85 million shs22.99 million shs
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$5.09
-0.4%
$4.55
$2.76
$6.00
$240.85M0.4115,423 shs2,878 shs
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.39
-3.1%
$0.37
$0.22
$3.37
$16.74M-0.413.16 million shs714,951 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aesther Healthcare Acquisition Corp. stock logo
AEHA
Aesther Healthcare Acquisition
0.00%0.00%0.00%0.00%+0.01%
Affimed stock logo
AFMD
Affimed
0.00%0.00%0.00%-76.44%-96.48%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-0.39%-3.69%+13.87%+54.71%-8.45%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-3.10%-6.15%+16.19%+10.53%-87.45%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aesther Healthcare Acquisition Corp. stock logo
AEHA
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Affimed stock logo
AFMD
Affimed
3.0405 of 5 stars
4.00.00.04.31.10.01.3
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
1.9167 of 5 stars
3.35.00.00.00.00.00.6
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.158 of 5 stars
0.03.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aesther Healthcare Acquisition Corp. stock logo
AEHA
Aesther Healthcare Acquisition
0.00
N/AN/AN/A
Affimed stock logo
AFMD
Affimed
2.00
Hold$3.621,895.87% Upside
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
2.50
Moderate Buy$8.0057.17% Upside
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AFMD, PRPH, AEHA, and NBTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Affimed stock logo
AFMD
Affimed
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/14/2025
Affimed stock logo
AFMD
Affimed
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/13/2025
Affimed stock logo
AFMD
Affimed
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/13/2025
Affimed stock logo
AFMD
Affimed
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$11.00 ➝ $0.10
5/13/2025
Affimed stock logo
AFMD
Affimed
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$5.00 ➝ $0.39
(Data available from 7/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aesther Healthcare Acquisition Corp. stock logo
AEHA
Aesther Healthcare Acquisition
N/AN/AN/AN/A($0.14) per shareN/A
Affimed stock logo
AFMD
Affimed
$877K3.33N/AN/A$4.19 per share0.04
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-$11.61M-20.67N/AN/A($1.51) per share-3.37
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$6.77M2.40N/AN/A$0.25 per share1.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aesther Healthcare Acquisition Corp. stock logo
AEHA
Aesther Healthcare Acquisition
-$560KN/A0.00N/AN/AN/AN/AN/A
Affimed stock logo
AFMD
Affimed
-$114.66MN/A0.00N/AN/A-7,836.26%-193.84%-107.24%9/1/2025 (Estimated)
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-$73.73MN/A0.00N/AN/AN/AN/AN/A9/17/2025 (Estimated)
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$53.36M-$1.26N/AN/AN/AN/A-184.38%-64.59%8/13/2025 (Estimated)

Latest AFMD, PRPH, AEHA, and NBTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$0.15N/AN/AN/A$3.55 millionN/A
5/20/2025Q1 2025
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aesther Healthcare Acquisition Corp. stock logo
AEHA
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/A
Affimed stock logo
AFMD
Affimed
N/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aesther Healthcare Acquisition Corp. stock logo
AEHA
Aesther Healthcare Acquisition
N/A
0.29
0.29
Affimed stock logo
AFMD
Affimed
0.13
1.93
1.93
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/A
1.04
1.04
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.30
1.03
0.98

Institutional Ownership

CompanyInstitutional Ownership
Aesther Healthcare Acquisition Corp. stock logo
AEHA
Aesther Healthcare Acquisition
78.64%
Affimed stock logo
AFMD
Affimed
30.82%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
38.81%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%

Insider Ownership

CompanyInsider Ownership
Aesther Healthcare Acquisition Corp. stock logo
AEHA
Aesther Healthcare Acquisition
19.80%
Affimed stock logo
AFMD
Affimed
3.80%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
3.45%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aesther Healthcare Acquisition Corp. stock logo
AEHA
Aesther Healthcare Acquisition
2,02113.23 million10.61 millionNot Optionable
Affimed stock logo
AFMD
Affimed
20016.10 million15.49 millionOptionable
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
10047.13 million45.51 millionNot Optionable
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
13041.54 million37.55 millionOptionable

Recent News About These Companies

ProPhase Labs Q1 2025 Earnings Preview
ProPhase Labs's Earnings Outlook
ProPhase Labs Delays Form 10-Q Filing

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aesther Healthcare Acquisition stock logo

Aesther Healthcare Acquisition NASDAQ:AEHA

Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the pharmaceutical and medical devices sectors. The company was incorporated in 2021 and is based in New York, New York.

Affimed stock logo

Affimed NASDAQ:AFMD

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Nanobiotix stock logo

Nanobiotix NASDAQ:NBTX

$5.09 -0.02 (-0.39%)
Closing price 07/22/2025 03:54 PM Eastern
Extended Trading
$5.07 -0.02 (-0.41%)
As of 08:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

ProPhase Labs stock logo

ProPhase Labs NASDAQ:PRPH

$0.39 -0.01 (-3.10%)
Closing price 07/22/2025 04:00 PM Eastern
Extended Trading
$0.39 +0.00 (+0.92%)
As of 09:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.